FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]

Pour des fins de recherche uniquement. Déclaration complète →

Recherche/Highlighting the emerging role of mitochondria-derived peptides (MDPs) in aging and disease could attract interest from researchers and clinicians interested in novel therapeutic targets.
Retour à la bibliothèque de recherche
humaninMOTS-cSHLPs

Highlighting the emerging role of mitochondria-derived peptides (MDPs) in aging and disease could attract interest from researchers and clinicians interested in novel therapeutic targets.

May 17, 2026
Share

Papier source

Mitochondria-derived peptides in aging and healthspan.

Miller Brendan et al.The Journal of clinical investigation2022
Recherche émergente

Basé sur des recherches émergentes. Ces découvertes sont prometteuses mais nécessitent une validation supplémentaire.

À propos de cette analyse

Cet article décompose les résultats du papier source ci-dessus dans un langage accessible pour la communauté de recherche en peptides. Notre objectif est d'highlighter ce qui compte le plus — les implications pratiques, la force des preuves et ce que cela signifie pour la recherche en cours.

Unveiling Mitochondria-Derived Peptides: A New Frontier in Aging Research

Published: May 17, 2026 | Source: The Journal of clinical investigation (2022) | Category: humanin, MOTS-c, SHLPs

Overview

Recent research highlights the potential role of mitochondria-derived peptides (MDPs) in aging and age-related diseases. These small proteins, encoded by mitochondrial DNA, could offer new insights into how cellular function declines with age and open up novel therapeutic avenues for conditions like type 2 diabetes, cancer, and neurodegenerative disorders.

Study Background

Mitochondrial dysfunction is a well-known hallmark of aging, contributing to various chronic diseases. However, the role of small proteins produced by mitochondria has been largely overlooked until recently. The review paper "Mitochondria-Derived Peptides in Aging and Healthspan" synthesizes current knowledge on MDPs, which are short peptides encoded by mitochondrial DNA (mtDNA) that play crucial roles in cellular health.

What the Research Found

The study reviews eight known MDPs: humanin, MOTS-c, and six small human longevity peptides (SHLPs). These peptides have been shown to influence various physiological processes, including glucose metabolism, insulin sensitivity, and inflammation. For instance, humanin has anti-apoptotic properties that protect against neuronal cell death, while MOTS-c enhances muscle function and metabolic health.

What This Means for Peptide Users

While the research is still in its early stages, understanding MDPs could lead to new therapeutic targets for age-related diseases. Future studies might uncover more about how these peptides interact with cellular pathways and identify potential drugs that mimic or enhance their effects. However, it's important to note that clinical applications are not yet available.

Limitations and Caveats

As a review paper, this study does not present original experimental data but rather synthesizes existing knowledge. The field of MDPs is still evolving, with many unanswered questions about their mechanisms of action and clinical implications. More research is needed to establish the full potential of these peptides in therapeutic contexts.

How This Compares to Previous Research

Previous studies have focused on larger mitochondrial proteins and broader aspects of mitochondrial function in aging. The novelty here lies in highlighting the role of small, previously underexplored peptides. While some researchers might argue that more experimental evidence is needed before drawing conclusions about MDPs' clinical relevance, this review provides a comprehensive overview of current knowledge.

Our Analysis

PeptideVault's analysis suggests that while the potential of mitochondria-derived peptides (MDPs) in aging and disease is promising, further research is essential to validate their therapeutic applications. The review effectively summarizes recent advances but acknowledges significant gaps in our understanding. Future studies should focus on elucidating MDPs' mechanisms and exploring their clinical utility.

Key Takeaways

  • Emerging Role: Mitochondria-derived peptides (MDPs) are gaining recognition for their potential roles in aging and age-related diseases.
  • Mechanistic Insights: Understanding how these small peptides interact with cellular pathways could lead to novel therapeutic targets.
  • Future Directions: More research is needed to validate the clinical relevance of MDPs and explore their full therapeutic potential.

Original Source

Citation: Miller Brendan, Kim Su-Jeong, Kumagai Hiroshi et al. (2022). Mitochondria-derived peptides in aging and healthspan.. The Journal of clinical investigation. DOI: 10.1172/JCI158449

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Note de l'éditeur

Cette analyse a été préparée par l'équipe de recherche de Peptide Contacts. Nous encourageons les lecteurs à vérifier les informations auprès du papier source complet pour la méthodologie et les données complètes. L'original de la publication est disponible sur le PubMed.

Recherches connexes

Comments

Sign in to join the discussion

Cette analyse est générée à partir d'une recherche peer-reviewed pour des fins éducatives uniquement. Elle ne constitue pas un avis médical. Consultez toujours un fournisseur de soins de santé qualifié avant d'utiliser tout traitement basé sur les peptides.